Baorui Liu

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 30

Top Topics

Monoclonal Antibody

Cancer Stem Cells

Top Venues

Future oncology (London, England)

Journal for immunotherapy of cancer

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

This page only lists publications with an associated author ORCID identifier.

Publications

Lei Lei, Jiayao Yan, Kai Xin, Lin Li, Qi Sun, Ying Wang, Tianran Chen, Siwen Wu, Jie Shao, Baorui Liu, Xiaotong Chen
Engineered Bacteriophage-Based In Situ Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity. ACS nano (2024)
Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) 20 (17) (2024)
Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) 20 (17) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) (2024)
Lei Lei, Jiayao Yan, Kai Xin, Lin Li, Qi Sun, Ying Wang, Tianran Chen, Siwen Wu, Jie Shao, Baorui Liu, Xiaotong Chen
Engineered Bacteriophage-Based In Situ Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity. ACS nano 18 (19) (2024)
Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) 20 (17) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) (2024)
Xinyue Wang, Fanyan Meng, Xiang Li, Luxin Xue, Anni Chen, Yuling Qiu, Zhifan Zhang, Lin Li, Fengcen Liu, Yishan Li, Zhichen Sun, Yanhong Chu, Ruihan Xu, Lixia Yu, Jie Shao, Manman Tian, Xiaoping Qian, Qin Liu, Baorui Liu, Ru-Tian Li
Nanomodified Switch Induced Precise and Moderate Activation of CAR-T Cells for Solid Tumors. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Zhichen Sun, Yanhong Chu, Jie Xiao, Yueling Yang, Fanyan Meng, Xinyue Wang, Yanbing Dong, Junmeng Zhu, Yirong Wu, Lanqun Qin, Yaohua Ke, Baorui Liu, Qin Liu
Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy. Journal of translational medicine 21 (1) (2023)
Ruihan Xu, Qin Wang, Junmeng Zhu, Yuncheng Bei, Yanhong Chu, Zhichen Sun, Shiyao Du, Shujuan Zhou, Naiqing Ding, Fanyan Meng, Baorui Liu
Membrane fusogenic nanoparticle-based HLA-peptide-addressing universal T cell receptor-engineered T (HAUL TCR-T) cell therapy in solid tumor. Bioengineering & translational medicine 8 (6) (2023)
Xinyue Wang, Fanyan Meng, Xiang Li, Luxin Xue, Anni Chen, Yuling Qiu, Zhifan Zhang, Lin Li, Fengcen Liu, Yishan Li, Zhichen Sun, Yanhong Chu, Ruihan Xu, Lixia Yu, Jie Shao, Manman Tian, Xiaoping Qian, Qin Liu, Baorui Liu, Ru-Tian Li
Nanomodified Switch Induced Precise and Moderate Activation of CAR-T Cells for Solid Tumors. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Jingyi Guo, Qun Zhou, Mingzhen Zhou, Hengheng Dai, Lin Li, Yudong Qiu, Liang Mao, Baorui Liu, Jie Shen
Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study. Cancer medicine (2023)
Jia Wei, Xiaofeng Lu, Qin Liu, Yao Fu, Song Liu, Yang Zhao, Jiawei Zhou, Hui Chen, Meng Wang, Lin Li, Ju Yang, Fangcen Liu, Liming Zheng, Haitao Yin, Yang Yang, Chong Zhou, Ping Zeng, Xiaoyu Zhou, Naiqing Ding, Shiqing Chen, Xiaochen Zhao, Jing Yan, Xiangshan Fan, Wenxian Guan, Baorui Liu
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial. Nature communications 14 (1) (2023)
Baorui Liu, Zhan Shi, Xin Zhang, Qin Liu, Xiaobin Cui, Lin Li, Baorui Liu, Jia Wei
Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer. Cancer medicine (2023)
Yipeng Zhang, Kaijie Liang, Xiaoyu Zhou, Xin Zhang, Hui Xu, Hongjiu Dai, Xueru Song, Xueyi Yang, Baorui Liu, Tao Shi, Jia Wei
Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer. Cancer science (2023)
Xinjie Chen, Lanqi Cen, Qin Liu, Yanhong Chu, Xiaoyu Feng, Yaohua Ke, Zhe Zhang, Hengheng Dai, Shuling Huang, Baorui Liu, Xiaoping Qian
A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma. Biomaterials science 10 (23) (2022)
Qin Liu, Yanhong Chu, Jie Shao, Hanqing Qian, Ju Yang, Huizi Sha, Lanqi Cen, Manman Tian, Qiuping Xu, Fangjun Chen, Yang Yang, Weifeng Wang, Kai Wang, Lixia Yu, Jia Wei, Baorui Liu
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2022)
Fanyan Meng, Jun Liu, Jia Wei, Baorui Liu, Chong Zhou, Jing Yan, Baorui Liu
Tumor-penetrating peptide internalizing RGD enhances radiotherapy efficacy through reducing tumor hypoxia. Cancer science 113 (4) (2022)
Yahui Zhu, Jing Zhou, Lijing Zhu, Wenjing Hu, Baorui Liu, Li Xie
Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Human vaccines & immunotherapeutics 18 (5) (2022)
Junmeng Zhu, Yaohua Ke, Qin Liu, Ju Yang, Fangcen Liu, Ruihan Xu, Hang Zhou, Aoxing Chen, Jie Xiao, Fanyan Meng, Lixia Yu, Rutian Li, Jia Wei, Baorui Liu
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nature communications 13 (1) (2022)
Hengheng Dai, Ying Huang, Jingyi Guo, Lin Li, Yaohua Ke, Lanqi Cen, Fanyan Meng, Xinjie Chen, Baorui Liu, Xiaoping Qian
Engineering a HemoMap Nanovaccine for Inducing Immune Responses against Melanoma. ACS applied materials & interfaces 14 (47) (2022)
Zhichen Sun, Rutian Li, Yun Shen, Siyi Tan, Naiqing Ding, Ruihan Xu, Xinyue Wang, Jia Wei, Baorui Liu, Fanyan Meng
In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. Journal of hematology & oncology 15 (1) (2022)
Qin Wang, Ying-Tzu Yen, Chen Xie, Fangcen Liu, Qin Liu, Jia Wei, Lixia Yu, Lifeng Wang, Fanyan Meng, Ru-Tian Li, Baorui Liu
Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells. Drug delivery 28 (1) (2021)
Xiaoxiao Yu, Jiayao Yan, Xiaotong Chen, Jia Wei, Lixia Yu, Fangcen Liu, Lin Li, Baorui Liu
Identification of a peptide binding to cancer antigen Kita-kyushu lung cancer antigen 1 from a phage-display library. Cancer science 112 (10) (2021)
Yanhong Chu, Rutian Li, Lingyu Qian, Fangcen Liu, Ruihan Xu, Fanyan Meng, Yaohua Ke, Jie Shao, Lixia Yu, Qin Liu, Baorui Liu
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination. Cancer science 112 (11) (2021)
Hanqing Qian, Keyang Qian, Juan Cai, Yan Yang, Lijing Zhu, Baorui Liu
Therapy for Gastric Cancer with Peritoneal Metastasis Using Injectable Albumin Hydrogel Hybridized with Paclitaxel-Loaded Red Blood Cell Membrane Nanoparticles. ACS biomaterials science & engineering 5 (2) (2019)